Lead Program

Aequus’ lead program is a transdermal application for the atypical anti-psychotic, Abilify. Abilify is a unique atypical anti-psychotic as it only partially binds to dopamine receptors compared to other drugs in this class that fully block receptors. This results in a “best-in-class” side effect profile, reducing the “treatment-related” factors for non-compliance. A transdermal application would complement this by targeting the “patient-related” factors that lead to non-compliance and ultimately relapse into an acute episode.

In addition to providing benefits to the patient with a transdermal application, the enhancement of the current formulation of a drug follows a “505(b)2” regulatory pathway, which has significantly reduced development costs, timelines and risks compared to a new drug application.